Imunon Inc
IMNN
Company Profile
Business description
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
Contact
997 Lenox Drive
Suite 100
LawrencevilleNJ08648
USAT: +1 609 896-9100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
25
Stocks News & Analysis
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
We plan to raise our fair value estimate of BlackRock stock.
stocks
Our view of ANZ’s strategic plan
Trying to please customers and shareholders with a simpler and leaner bank.
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,299.00 | 21.90 | 0.24% |
| CAC 40 | 8,114.23 | 194.61 | 2.46% |
| DAX 40 | 24,281.76 | 44.82 | 0.18% |
| Dow JONES (US) | 46,270.46 | 202.88 | 0.44% |
| FTSE 100 | 9,400.68 | 52.09 | -0.55% |
| HKSE | 25,910.60 | 469.25 | 1.84% |
| NASDAQ | 22,521.70 | 172.91 | -0.76% |
| Nikkei 225 | 47,672.67 | 825.35 | 1.76% |
| NZX 50 Index | 13,307.40 | 30.41 | 0.23% |
| S&P 500 | 6,644.31 | 10.41 | -0.16% |
| S&P/ASX 200 | 8,990.90 | 22.20 | 0.25% |
| SSE Composite Index | 3,912.21 | 46.98 | 1.22% |